Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5645604 | Clinical Skin Cancer | 2016 | 14 Pages |
Abstract
Ivermectin is a promising agent that could strongly increase melanoma therapy efficiency because it is cytotoxic for BRAF-wt and BRAF mutated melanomas and because it increases the efficiency of antimutated BRAF inhibitors independent of the BRAF status of tumors. Because ivermectin is FDA approved and a study of ivermectin would be able to include all patients in the same protocol, this combination treatment should be next investigated in clinical studies.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Franck Gallardo, Iotefa Teiti, Philippe Rochaix, Eloise Demilly, Denis Jullien, Bernard Mariamé, Anne-Françoise Tilkin-Mariamé,